PMID- 19211266 OWN - NLM STAT- MEDLINE DCOM- 20100108 LR - 20091102 IS - 1879-1336 (Electronic) IS - 1054-8807 (Linking) VI - 18 IP - 6 DP - 2009 Nov-Dec TI - Relationship between circulating levels of monocyte chemoattractant protein-1 and systolic dysfunction in patients with hypertrophic cardiomyopathy. PG - 317-22 LID - 10.1016/j.carpath.2008.12.004 [doi] AB - BACKGROUND: Progression of hypertrophic cardiomyopathy (HCM) to left ventricular dilatation and systolic dysfunction sometimes occurs. However, the mechanism of the transition from hypertrophy to dysfunction has not been elucidated. It has been reported that circulating levels of monocyte chemoattractant protein-1 (MCP-1), which is a major factor promoting the accumulation of macrophages, are increased in patients with congestive heart failure. We measured circulating levels of MCP-1 in patients with HCM and examined whether MCP-1 was expressed in the myocardium of HCM patients. We also examined whether circulating levels of MCP-1 were correlated with left ventricular dysfunction. METHODS: Circulating levels of MCP-1 were measured by an enzyme immunoassay in 26 patients with HCM (60+/-2 years old) and 20 control subjects (57+/-2 years old). Cardiac function was evaluated by two-dimensional echocardiography and cardiac catheterization. RESULTS: HCM patients had significantly elevated levels of MCP-1 (HCM: 309+/-30 vs. control: 178+/-8 pg/ml, P<.001). MCP-1 levels in patients with systolic dysfunction were significantly higher than those in patients without systolic dysfunction (P<.05) and were also significantly higher than those in patients with outflow obstruction (P<.05). Immunohistochemical analysis revealed that MCP-1 was expressed in endomyocardial biopsy samples obtained from HCM patients with systolic dysfunction. Furthermore, MCP-1 levels were inversely correlated with fractional shortening (r=-.401, P<.05) and correlated with left ventricular end-diastolic pressure (r=-.579, P<.01). CONCLUSION: These results show that MCP-1 is associated with, and might be involved in the pathogenesis of, left ventricular systolic dysfunction in patients with HCM. FAU - Iwasaki, Jun AU - Iwasaki J AD - Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Shikata-cho, Okayama, Japan. FAU - Nakamura, Kazufumi AU - Nakamura K FAU - Matsubara, Hiromi AU - Matsubara H FAU - Nakamura, Yoichi AU - Nakamura Y FAU - Nishii, Nobuhiro AU - Nishii N FAU - Banba, Kimikazu AU - Banba K FAU - Murakami, Masato AU - Murakami M FAU - Ohta-Ogo, Keiko AU - Ohta-Ogo K FAU - Kimura, Hideo AU - Kimura H FAU - Toh, Norihisa AU - Toh N FAU - Nagase, Satoshi AU - Nagase S FAU - Oka, Takefumi AU - Oka T FAU - Morita, Hiroshi AU - Morita H FAU - Kusano, Kengo Fukushima AU - Kusano KF FAU - Ohe, Tohru AU - Ohe T LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20090211 PL - United States TA - Cardiovasc Pathol JT - Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology JID - 9212060 RN - 0 (CCL2 protein, human) RN - 0 (Chemokine CCL2) SB - IM MH - Cardiomyopathy, Hypertrophic/*blood/*complications MH - Chemokine CCL2/biosynthesis/*blood MH - Disease Progression MH - Enzyme-Linked Immunosorbent Assay MH - Female MH - Humans MH - Immunohistochemistry MH - Male MH - Middle Aged MH - Myocardium/metabolism MH - Ventricular Dysfunction, Left/*blood/*complications EDAT- 2009/02/13 09:00 MHDA- 2010/01/09 06:00 CRDT- 2009/02/13 09:00 PHST- 2008/01/15 00:00 [received] PHST- 2008/10/29 00:00 [revised] PHST- 2008/12/03 00:00 [accepted] PHST- 2009/02/13 09:00 [entrez] PHST- 2009/02/13 09:00 [pubmed] PHST- 2010/01/09 06:00 [medline] AID - S1054-8807(08)00185-3 [pii] AID - 10.1016/j.carpath.2008.12.004 [doi] PST - ppublish SO - Cardiovasc Pathol. 2009 Nov-Dec;18(6):317-22. doi: 10.1016/j.carpath.2008.12.004. Epub 2009 Feb 11.